Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.
复制标题

DOI:
10.1016/j.yjmcc.2014.05.016
复制
发表时间:
2014-09
影响因子:
5
通讯作者:
Seubert, John M.
Seubert, John M.
中科院分区:
医学2区
文献类型:
--
作者:
Oni-Orisan, Akinyemi;Alsaleh, Nasser;Lee, Craig R.;Seubert, John M.

文献摘要

参考文献

被引文献

相似文献

心血管疾病,包括急性心肌梗死(AMI),是全球发病率和死亡率的主要原因,尽管有成熟的治疗方法。因此,发现和开发预防AMI后破坏性后果进展的新疗法对于减少这种破坏性疾病的全球负担非常重要。环氧二十碳三烯酸(ESTs)在心血管系统中的保护作用的科学证据正在迅速出现,并表明促进这些细胞色素P450衍生的环氧二十烷酸的作用是一种潜在可行的临床治疗策略。通过一个平移的透镜,本综述将通过以下方式深入了解这种治疗策略对AMI的潜在临床应用:1)概述了已知的Eclase的心脏保护作用及其在AMI临床前模型中表现出的潜在机制,特别关注心肌缺血-再灌注损伤,2)描述了在人类队列中的研究,这些研究证明了雌二醇和相关途径与冠状动脉疾病风险之间的关系,和3)讨论需要进一步研究的临床前和临床领域,以增加成功地将这一迅速出现的证据体转化为临床适用的AMI治疗策略的可能性。
Cardiovascular disease, including acute myocardial infarction (AMI), is the leading cause of morbidity and mortality globally, despite well-established treatments. The discovery and development of novel therapeutics that prevent the progression of devastating consequences following AMI are thus important in reducing the global burden of this devastating disease. Scientific evidence for the protective effects of epoxyeicosatrienoic acids (EETs) in the cardiovascular system is rapidly emerging and suggests that promoting the effects of these cytochrome P450-derived epoxyeicosanoids is a potentially viable clinical therapeutic strategy. Through a translational lens, this review will provide insight into the potential clinical utility of this therapeutic strategy for AMI by 1) outlining the known cardioprotective effects of EETs and underlying mechanisms demonstrated in preclinical models of AMI with a particular focus on myocardial ischemia–reperfusion injury, 2) describing studies in human cohorts that demonstrate a relationship between EETs and associated pathways with coronary artery disease risk, and 3) discussing preclinical and clinical areas that require further investigation in order to increase the probability of successfully translating this rapidly emerging body of evidence into a clinically applicable therapeutic strategy for AMI.
DOI: 10.1016/j.yjmcc.2009.10.022
发表时间: 2010-02
影响因子: 5
作者:
Deng Y;Theken KN;Lee CR
通讯作者: Lee CR
DOI: 10.1111/j.1476-5381.2010.01093.x
发表时间: 2011-02-01
影响因子: 7.3
作者:
Batchu, S. N.;Lee, S. B.;Seubert, J. M.
通讯作者: Seubert, J. M.
DOI: 10.1124/dmd.106.012823
发表时间: 2007-04-01
影响因子: 3.9
作者:
DeLozier, Tracy C.;Kissling, Grace E.;Goldstein, Joyce A.
通讯作者: Goldstein, Joyce A.
DOI: 10.1096/fj.10-171488
发表时间: 2011-02-01
期刊: FASEB JOURNAL
影响因子: 4.8
作者:
Deng, Yangmei;Edin, Matthew L.;Lee, Craig R.
通讯作者: Lee, Craig R.
DOI: 10.1097/fjc.0b013e3181c37d69
发表时间: 2010-01
影响因子: 3
作者:
Chaudhary KR;Abukhashim M;Hwang SH;Hammock BD;Seubert JM
通讯作者: Seubert JM